E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060862 |
E.1.2 | Term | Prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
In men with low risk prostate cancer, who seek to adopt expectant management (active surveillance or deferred radical therapy)does exposure to 0.5mg dutasteride once daily for six months result in a change in volume of prostate cancer, as assessed by MRI (T2 weighted)?
|
|
E.2.2 | Secondary objectives of the trial |
In men with low risk prostate cancer, who seek to adopt expectant management (active surveillance or deferred radical therapy)does exposure to 0.5mg dutasteride once daily result in:
1. Change in volume of prostate cancer as determined by each of a) gadolinium enhanced b) diffusion weighted MRI after 6 months of dutasteride (Avodart) 0.5mg compared to placebo. 2. Change in volume of prostate cancer as determined by each of a) T2 weighted MRI b) gadolinium enhanced MRI c) diffusion weighted MRI after 3 months of dutasteride (Avodart) 0.5mg compared to placebo. 3. Changes in MR characteristics of prostate cancer (perfusion, cell density) between baseline and six months in men on dutasteride (Avodart) 0.5mg compared to placebo. 4. Change in volume of prostate cancer as assessed by HistoScan transrectal ultrasound between baseline and six months. 5. An association between the measured prostate cancer volumes on MRI with the measured prostate cancer volumes on HistoScan at baseli |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria • Men with low risk prostate cancer: Gleason sum 6 or less, PSA less than 15 ng/ml, T1c to T2a • Measurable disease on MRI of at least 0.2 cc, based on planimetry volume • Biopsy proven disease within 2 years of screening visit • Able to swallow and retain oral medication • Able and willing to participate in the study for its duration • Able to read and write (health outcomes questionnaires are written) • Able to understand instructions related to study procedures and give written informed consent.
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria A subject will not be eligible for inclusion in this study if any of the following criteria apply:
1. Subject has ever been treated for prostate cancer with any of the following: • Radiotherapy (external beam or brachytherapy) • Chemotherapy Surgery • Hormonal therapy (e.g., megestrol, medroxyprogesterone, cyproterone, DES) • Oral glucocorticoids • GnRH analogues (e.g., leuprolide, goserelin)
2. Glucocorticoids, except inhaled or topical, are not permitted within 3 months prior to visit one.
3. Current and/or previous use of the following medications: • Finasteride (Proscar, Propecia), or Dutasteride (GI198745, AVODART) exposure within 12 months prior to study entry are excluded. • Any other investigational 5α-reductase inhibitors within the past 12 months. • Anabolic steroids (subject must discontinued for 6 months prior to study entry to be eligible) • Drugs with antiandrogenic properties within the past 6 months (e.g., spironolactone, flutamide, bicalutamide, *cimetidine, *ketoconazole, metronidazole, progestational agents) NOTE: Use of dietary and herbal supplements (e.g., selenium, Vitamin E, saw palmetto) during the study is discouraged but not prohibited. All dietary and herbal supplement usage will be recorded in the CRF. *The use of cimetidine is permitted prior to study entry. The use of topical ketoconazole is permitted prior to and during the study
4. Contra indication on gadolinium enhanced MRI: inability to see tumour focus of >/= 0.2cc on T2 sequences Previous allergic reaction to gadolinium Serum creatinine > upper limit normal Incompatible pacemaker Metal fragments in eyes Hip replacements which give artefact with prostate /pelvis views Any artefact or condition which reduces image quality of MRI (eg inability to keep still).
5. Subject has had prior prostatic surgery including TUNA, TURP, TUIP, laser treatment, thermotherapy, balloon dilatation, prosthesis, and ultrasound ablation within 3 months of involvement.
6. Participation in any investigational or marketed drug trial within the 30 days prior to the first dose of study drug or anytime during the study period.
7. Any unstable serious co-existing medical condition(s) including but not limited to: myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to Screening visit; uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management.
8. Abnormal liver function test (greater than 2 times the upper limit of normal) for • alanine aminotransferase [ALT], aspartate aminotransferase [AST], or alkaline • phosphatase [ALP]); or bilirubin >1.5 times the upper limit of normal.
9. An estimated glomerular filtration rate (eGFR) of less than 60 ml/kg/1.73m2, as given by UCLH laboratories, due to the risk of a deterioration in renal function with MRI contrast.
11. History of another malignancy within five years that could affect the diagnosis of prostate cancer.
12. History or current evidence of drug or alcohol abuse within the last 12 months which might confound the results of the study or pose additional risk to the subject. 13. Known hypersensitivity to any 5α-reductase inhibitor, soya, peanut, or any other excipients; or to any drug chemically related to dutasteride.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is percentage change in volume of prostate cancer as assessed by T2 weighted MRI at baseline and six months. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Completion of all trial procedures by participants (follow up and results obtained) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |